Subsidiary of Zhejiang Jiuzhou Pharmaceutical (603456.SH) obtains "Drug Production License".

Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced recently that its wholly-owned subsidiary, Zhejiang Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. (referred to as "Zhejiang Jiuzhou Pharmaceutical (Taizhou)"), has received the "Drug Production License" issued by the Zhejiang Provincial Drug Administration. The production address and range are: No.19 East Hai Eighth Avenue, Taizhou Bay Economic and Technological Development Zone, Linhai City, Taizhou City, Zhejiang Province (self-declared): API***. This is the first time that the wholly-owned subsidiary Zhejiang Jiuzhou Pharmaceutical (Taizhou) has obtained the "Drug Production License", which is beneficial for promoting the development of the company's CDMO business and further enhancing its business capabilities. Zhejiang Jiuzhou Pharmaceutical (Taizhou) still needs to obtain a drug approval number and pass GMP certification before commercial production can take place. The acquisition of the "Drug Production License" will not have a significant impact on the company's performance in the short term.